Observational, Data Collection Study for Subjects With Diabetes Using Insulin Injections
1 other identifier
observational
260
1 country
1
Brief Summary
This is an observational, multicenter prospective study including up to 260 subjects with type 1 or type 2 diabetes who use insulin injections (either basal insulin only or multiple daily injections (MDI)) and CGM or SMBG to manage their diabetes. The study aims to generate the database needed for future development and verification of insulin-glucose modules of subjects with diabetes using insulin injections. During the study, subjects will continue their regular diabetes management using their regular glucose monitoring method (either CGM or SMBG), insulin injections and oral medication (as applicable). Subjects will be requested to document glucose levels and insulin delivery during basal only or basal/bolus insulin treatment. In addition, subjects will have their daily activities recorded (meals, physical activity etc) using electronic log (implemented on the CGM/FGM receiver, Dedicated App, Neura App and/or other logbooks). Data will be captured during regular daily life using Insulin Connected pens and daily diary application software, for a period of 1 month.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2019
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 8, 2019
CompletedFirst Posted
Study publicly available on registry
July 10, 2019
CompletedStudy Start
First participant enrolled
September 20, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2020
CompletedDecember 26, 2019
December 1, 2019
6 months
July 8, 2019
December 22, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Glucose levels
Characterise the insulin-glucose dynamics for insulin users
1 month
Study Arms (2)
Type 1 Diabetes
Type 2 Diabetes
Interventions
Basal/ Bolus insulin injections
Eligibility Criteria
Up to 260 subjects with diabetes mellitus will be recruited in the following distribution: up to 100 T1D and up to 160 T2D. All subjects will be using multiple daily injections of insulin or basal injections only and self-monitoring blood glucose or continuous glucose monitoring.
You may qualify if:
- Documented T1D or T2D for at least 1 year prior to study enrolment
- T1D: Subjects aged 1 year or older
- T2D: Subjects aged 30 years or older
- Subjects using basal-bolus MDI therapy or basal insulin only - basal insulin Lantus or Tregludec and any short acting insulin.
- T2D: Insulin pumps will also be accepted.
- T2D: BMI ≥ 25 kg/m2
- Subjects willing to follow study instructions:
- For SMBG users: measure capillary blood glucose at least 4 times a day and twice a week 7-point profile. Document blood glucose level, insulin delivery, meals and daily activities. Optional: wear blinded CGM.
- For CGM users: Document insulin delivery, meals and daily activities. Optional:
- Measure capillary blood glucose in addition.
- Adult subjects or parents of pediatric subjects willing and able to sign a written informed consent form.
You may not qualify if:
- An episode of diabetic keto-acidosis within the month prior to study entry and/or severe hypoglycemia resulting in seizure or loss of consciousness in the month prior to enrolment.
- Concomitant diseases/ treatment that influence metabolic control (except diabetes treatment for T2) or any significant diseases /conditions including psychiatric disorders and substance abuse that in the opinion of the investigator is likely to affect the subject's ability to complete the study or compromise subject's safety
- T2D: eGFR \< 60
- Participation in any other interventional study
- Female subject who is pregnant or planning to become pregnant within the planned study duration
- T1D: Subject is in the "honeymoon" phase - i.e. less than 0.5 insulin units/kg per day.
- Drug or alcohol abuse.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- DreaMed Diabeteslead
Study Sites (1)
Scheider MC
Petah Tikva, 4952805, Israel
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 8, 2019
First Posted
July 10, 2019
Study Start
September 20, 2019
Primary Completion
April 1, 2020
Study Completion
April 1, 2020
Last Updated
December 26, 2019
Record last verified: 2019-12
Data Sharing
- IPD Sharing
- Will not share